Search results
Results from the WOW.Com Content Network
The center is focused on detecting the genetic causes of prevalent childhood diseases including asthma, obesity, ADHD, autism, diabetes, inflammatory bowel disease, epilepsy, schizophrenia, and pediatric cancer, all of which are thought to potentially involve multiple, interacting genes within the body.
Mardepodect is currently one of the furthest advanced PDE 10A inhibitors in development and has progressed through to Phase II clinical trials in humans. [5] In 2017, development of mardepodect for the treatment of schizophrenia and Huntington's disease was discontinued.
Born: 1948 (age 76–77) Education: Miami University George Washington University (): Known for: Schizophrenia research NIMH CATIE study [1]: Children: 2: Awards: Lieber Prize for Schizophrenia Research from the National Association for Research in Schizophrenia and Affective Disorders
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...
In the previous study, luvadaxistat failed to meet the main goal of change from baseline in negative symptoms of schizophrenia, however, it met the secondary goal of improving cognitive performance.
He is the original author of the landmark neurodevelopmental hypothesis of schizophrenia (first published in The Neurology of Schizophrenia, Elsevier, 1986) [12] and in the more cited reference, Arch Gen Psychiatry 1987, (the most cited publication [>4100 citations] about the biology of schizophrenia in Google Scholar).
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT 2A and σ 2 receptor antagonist under development by Minerva Neurosciences for the treatment of schizophrenia.